As of 2025-07-09, the Relative Valuation of GT Biopharma Inc (GTBP) is (67.43) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.05 USD, the upside of GT Biopharma Inc based on Relative Valuation is -3389.3%.
The range of the Relative Valuation is (56.75) - (109.02) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.4x - 48.1x | 26.9x |
| Forward P/E multiples | 25.0x - 51.6x | 32.6x |
| Fair Price | (56.75) - (109.02) | (67.43) |
| Upside | -2868.5% - -5418.1% | -3389.3% |
| Date | P/E |
| 2025-07-03 | -1.23 |
| 2025-07-02 | -1.37 |
| 2025-07-01 | -1.50 |
| 2025-06-30 | -1.58 |
| 2025-06-27 | -1.56 |
| 2025-06-26 | -1.68 |
| 2025-06-25 | -1.48 |
| 2025-06-24 | -1.46 |
| 2025-06-23 | -1.42 |
| 2025-06-20 | -1.35 |
| 2025-06-18 | -1.30 |
| 2025-06-17 | -1.24 |
| 2025-06-16 | -1.24 |
| 2025-06-13 | -1.25 |
| 2025-06-12 | -1.24 |
| 2025-06-11 | -1.40 |
| 2025-06-10 | -1.34 |
| 2025-06-09 | -1.33 |
| 2025-06-06 | -1.18 |
| 2025-06-05 | -1.19 |
| 2025-06-04 | -1.19 |
| 2025-06-03 | -1.24 |
| 2025-06-02 | -1.20 |
| 2025-05-30 | -1.14 |
| 2025-05-29 | -1.19 |
| 2025-05-28 | -1.25 |
| 2025-05-27 | -1.28 |
| 2025-05-23 | -1.28 |
| 2025-05-22 | -1.18 |
| 2025-05-21 | -1.17 |
| 2025-05-20 | -0.96 |
| 2025-05-19 | -0.99 |
| 2025-05-16 | -0.98 |
| 2025-05-15 | -0.99 |
| 2025-05-14 | -0.97 |
| 2025-05-13 | -0.96 |
| 2025-05-12 | -1.01 |
| 2025-05-09 | -1.00 |
| 2025-05-08 | -1.03 |
| 2025-05-07 | -1.05 |
| 2025-05-06 | -1.05 |
| 2025-05-05 | -1.01 |
| 2025-05-02 | -1.03 |
| 2025-05-01 | -1.08 |
| 2025-04-30 | -1.07 |
| 2025-04-29 | -1.01 |
| 2025-04-28 | -1.01 |
| 2025-04-25 | -1.01 |
| 2025-04-24 | -1.01 |
| 2025-04-23 | -0.98 |